Search

Your search keyword '"Katsaròs, Dionyssios"' showing total 24 results
Start Over Author "Katsaròs, Dionyssios"
24 results on '"Katsaròs, Dionyssios"'

1. Prognostic impact and causality of age on oncological outcomes in women with endometrial cancer: a multimethod analysis of the randomised PORTEC-1, PORTEC-2, and PORTEC-3 trials

Author

Wakkerman, Famke C, Wu, Jiqing, Putter, Hein, Jürgenliemk-Schulz, Ina M, Jobsen, Jan J, Lutgens, Ludy C H W, Haverkort, Marie A D, de Jong, Marianne A, Mens, Jan Willem M, Wortman, Bastiaan G, Nout, Remi A, Léon-Castillo, Alicia, Powell, Melanie E, Mileshkin, Linda R, Katsaros, Dionyssios, Alfieri, Joanne, Leary, Alexandra, Singh, Naveena, de Boer, Stephanie M, Nijman, Hans W, Smit, Vincent T H B M, Bosse, Tjalling, Koelzer, Viktor H, Creutzberg, Carien L, and Horeweg, Nanda

Published
2024
Full Text
View/download PDF

2. Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial

Author

Abadie-Lacourtoisie, Sophie, Andreetta, Claudia, Anzizar, Nerea, Aoki, Daiseuke, Barretina-Ginesta, Maria-Pilar, Battista, Marco, Bellier, Charlotte, Bentzen, Anne Gry, Berton, Dominique, Billemont, Bertrand, Bjørge, Line, Bjurberg, Maria, Black, Destin, Bologna, Alessandra, Braicu, Elena Ioana, Casanova, Claudia, Chekerov, Radoslav, Chevalier, Annick, Cueva, Juan Fernando, Czogalla, Bastian, Delanoy, Nicolas, Denschlag, Dominik, Derke, Oscar, Eichbaum, Michael, Enomoto, Takayuki, Esteban, Carmen, Fabbro, Michel, Fehm, Tanja, Ferrero, Annamaria, Fleisch, Markus, Floquet, Anne, Frassoldati, Antonio, Gaba, Lydia, Gadducci, Angiolo, García, Yolanda, Geuna, Elena, Guerra, Eva, Hanker, Lars, Hardy-Bessard, Anne-Claire, Harter, Philipp, Hasegawa, Kosei, Hellman, Kristina, Herrero, Ana, Hilpert, Felix, Katsaros, Dionyssios, Koegel, Matthias, Koliadi, Anthoula, Kurtz, Jean-Emmanuel, Lampe, Bjoern, Lissoni, Andrea Alberto, Lortholary, Alain, Mangili, Giorgia, Mansi, Laura, Marmé, Frederik, Mathews, Cara, Mina, William, Minobe, Shinichiro, Moxley, Katherine, Nagao, Shoji, Nicoletto, Ornella, Nishino, Koji, Nishio, Hiroshi, Nishio, Shin, Oaknin, Ana, Onstad, Michaela, Pardo, Beatriz, Pérez-Fidalgo, J Alejandro, Pisano, Carmela, Poveda, Andrés, Radosa, Julia, Randall, Leslie M., Ray-Coquard, Isabelle, Redondo, Andrés, Richardson, Debra, Romero, Ignacio, Ronzino, Graziana, Rubio, Maria Jesús, Selle, Frederic, Takekuma, Munetaka, Takeshima, Nobuhiro, Tasca, Giulia, Tewari, Krishnansu, Todo, Yukiharu, Valabrega, Giorgio, Wimberger, Pauline, Woelber, Linn, Yamaguchi, Satoshi, You, Benoît, Yunokawa, Mayu, Gladieff, Laurence, Martínez-García, Jerónimo, Villacampa, Guillermo, De Giorgi, Ugo, Lindemann, Kristina, Colombo, Nicoletta, Duska, Linda, Leary, Alexandra, Godoy-Ortiz, Ana, Angelergues, Antoine, Fariñas-Madrid, Lorena, Lorusso, Domenica, Manso, Luis, Joly, Florence, Alarcón, Jesús, Follana, Philippe, Lebreton, Coriolan, Dahlstrand, Hanna, D'Hondt, Véronique, and Randall, Leslie M

Published
2024
Full Text
View/download PDF

3. Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup

Author

Mahner, Sven, Reuss, Alexander, du Bois, Andreas, Grimm, Christoph, Marth, Christian, Berger, Regina, Concin, Nicole, Chang, Ting-Chang, Ochiai, Kazunori, Gebski, Val, Davis, Alison, Beale, Philip, Vergote, Ignace, Kridelka, Frédéric, Denys, Hannelore, Vandecaveye, Vincent, Candido dos Reis, Francisco Jose, Del Pilar Estevez Diz, Maria, Stuart, Gavin, MacKay, Helen, Carey, Mark, Cibula, David, Dundr (path), Pavel, Dorigo, Oliver, Berek, Jonathan, O'Donnell, Dearbhaile, Saadeh, Abu, Boere, Ingrid, Lok, Christianne, Coronado, Pluvio, Ottevanger, Nelleke, Tan, David SP, Ng, Joseph, Gonzalez Martin, Antonio, Oaknin, Ana, Poveda, Andres, Perez Fidalgo, Alejandro, Rauh-Hain, Alejandro, Lu, Karen, López-Zavala, Carlos, Gómez-García, Eva María, Ray-Coquard, Isabelle, Paoletti, Xavier, Kurtz, Jean-Emmanuel, Joly, Florence, Votan, Bénédicte, Bookman, Michael, Moore, Kathleen, Arend, Rebecca, Fujiwara, Keiichi, Fujiwara, Hiroyuki, Hasegawa, Kosei, Bruchim, Ilan, Tsoref, Dalia, Oda, Katsutoshi, Okamoto, Aikou, Enomoto, Takayuki, Michel, Dayana, Kim, Hee-Seung, Lee, Jung-Yun, Mukhopadhyay, Asima, Katsaros, Dionyssios, Colombo, Nicoletta, Pignata, Sandro, Lorusso, Domenica, Scambia, Giovanni, Kohn, Elise, Lee, Jung-Min, McNeish, Iain, Nicum, Shibani, Farrelly, Laura, Sehouli, Jalid, Keller, Maren, Braicu, Elena, Bjørge, Line, Mirza, Mansoor Raza, Auranen, Annika, Welch, Stephen, Oza, Amit M, Heinzelmann, Viola, Gourley, Charlie, Roxburgh, Patricia, Herrington, C Simon, Glasspool, Ros, Zang, Rongyu, Zhu, Jianqing, Gonzalez-Martin, Antonio, Kohn, Elise C, Berek, Jonathan S, Tan, David S P, Stuart, Gavin C E, and Bookman, Michael A

Published
2022
Full Text
View/download PDF

4. Radiation Therapy Techniques and Treatment-Related Toxicity in the PORTEC-3 Trial: Comparison of 3-Dimensional Conformal Radiation Therapy Versus Intensity-Modulated Radiation Therapy

Author

Wortman, Bastiaan G., Post, Cathalijne C.B., Powell, Melanie E., Khaw, Pearly, Fyles, Anthony, D'Amico, Romerai, Haie-Meder, Christine, Jürgenliemk-Schulz, Ina M., McCormack, Mary, Do, Viet, Katsaros, Dionyssios, Bessette, Paul, Baron, Marie Hélène, Nout, Remi A., Whitmarsh, Karen, Mileshkin, Linda, Lutgens, Ludy C.H.W., Kitchener, Henry C., Brooks, Susan, Nijman, Hans W., Astreinidou, Eleftheria, Putter, Hein, Creutzberg, Carien L., and de Boer, Stephanie M.

Published
2022
Full Text
View/download PDF

5. Long-Term Toxicity and Health-Related Quality of Life After Adjuvant Chemoradiation Therapy or Radiation Therapy Alone for High-Risk Endometrial Cancer in the Randomized PORTEC-3 Trial

Author

Post, Cathalijne C.B., de Boer, Stephanie M., Powell, Melanie E., Mileshkin, Linda, Katsaros, Dionyssios, Bessette, Paul, Haie-Meder, Christine, Ottevanger, Nelleke (P.) B., Ledermann, Jonathan A., Khaw, Pearly, D'Amico, Romerai, Fyles, Anthony, Baron, Marie Hélène, Kitchener, Henry C., Nijman, Hans W., Lutgens, Ludy C.H.W., Brooks, Susan, Jürgenliemk-Schulz, Ina M., Feeney, Amanda, Goss, Geraldine, Fossati, Roldano, Ghatage, Prafull, Leary, Alexandra, Do, Viet, Lissoni, Andrea A., McCormack, Mary, Nout, Remi A., Verhoeven-Adema, Karen W., Smit, Vincent T.H.B.M., Putter, Hein, and Creutzberg, Carien L.

Published
2021
Full Text
View/download PDF

6. Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial

Author

McCormack, M, Whitmarsh, K, Allerton, R, Gregory, D, Symonds, P, Hoskin, PJ, Adusumalli, M, Anand, A, Wade, R, Stewart, A, Taylor, W, Lutgens, LCHW, Hollema, H, Pras, E, Snyers, A, Westerveld, GH, Jobsen, JJ, Slot, A, Mens, JM, Stam, TC, Van Triest, B, Van der Steen-Banasik, EM, De Winter, KAJ, Quinn, MA, Kolodziej, I, Pyman, J, Johnson, C, Capp, A, Fossati, R, Colombo, A, Carinelli, S, Ferrero, A, Artioli, G, Davidson, C, McLachlin, CM, Ghatage, P, Rittenberg, PVC, Souhami, L, Thomas, G, Duvillard, P, Berton-Rigaud, D, Tubiana-Mathieu, N, de Boer, Stephanie M, Powell, Melanie E, Mileshkin, Linda, Katsaros, Dionyssios, Bessette, Paul, Haie-Meder, Christine, Ottevanger, Petronella B, Ledermann, Jonathan A, Khaw, Pearly, D'Amico, Romerai, Fyles, Anthony, Baron, Marie-Helene, Jürgenliemk-Schulz, Ina M, Kitchener, Henry C, Nijman, Hans W, Wilson, Godfrey, Brooks, Susan, Gribaudo, Sergio, Provencher, Diane, Hanzen, Chantal, Kruitwagen, Roy F, Smit, Vincent T H B M, Singh, Naveena, Do, Viet, Lissoni, Andrea, Nout, Remi A, Feeney, Amanda, Verhoeven-Adema, Karen W, Putter, Hein, and Creutzberg, Carien L

Published
2019
Full Text
View/download PDF

7. 3408: Ten-year results of the PORTEC-3 trial: adjuvant therapy for women with high-risk endometrial cancer

Author

Post, Cathalijne C B, de Boer, Stephanie M., Powell, Melanie E., Mileshkin, Linda, Katsaros, Dionyssios, Bessette, Paul, Leary, Alexandra, Ottevanger, Nelleke P., McCormack, Mary, Khaw, Pearly, D’Amico, Romerai, Fyles, Anthony, Chargari, Cyrus, Kitchener, Henry C., Nijman, Hans W., Lutgens, Ludy, Jürgenliemk-Schulz, Ina M., Nout, Remi A., Putter, Hein, Horeweg, Nanda, Bosse, Tjalling, and Creutzberg, Carien L.

Published
2024
Full Text
View/download PDF

9. Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial

Author

de Boer, Stephanie M, Powell, Melanie E, Mileshkin, Linda, Katsaros, Dionyssios, Bessette, Paul, Haie-Meder, Christine, Ottevanger, Petronella B, Ledermann, Jonathan A, Khaw, Pearly, Colombo, Alessandro, Fyles, Anthony, Baron, Marie-Helene, Kitchener, Henry C, Nijman, Hans W, Kruitwagen, Roy F, Nout, Remi A, Verhoeven-Adema, Karen W, Smit, Vincent T, Putter, Hein, and Creutzberg, Carien L

Published
2016
Full Text
View/download PDF

11. Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial

Author

Pignata, Sandro, Scambia, Giovanni, Katsaros, Dionyssios, Gallo, Ciro, Pujade-Lauraine, Eric, De Placido, Sabino, Bologna, Alessandra, Weber, Beatrice, Raspagliesi, Francesco, Panici, Pierluigi Benedetti, Cormio, Gennaro, Sorio, Roberto, Cavazzini, Maria Giovanna, Ferrandina, Gabriella, Breda, Enrico, Murgia, Viviana, Sacco, Cosimo, Cinieri, Saverio, Salutari, Vanda, Ricci, Caterina, Pisano, Carmela, Greggi, Stefano, Lauria, Rossella, Lorusso, Domenica, Marchetti, Claudia, Selvaggi, Luigi, Signoriello, Simona, Piccirillo, Maria Carmela, Di Maio, Massimo, and Perrone, Francesco

Published
2014
Full Text
View/download PDF

13. Genomic and Epigenetic Alterations Deregulate microRNA Expression in Human Epithelial Ovarian Cancer

Author

Zhang, Lin, Volinia, Stefano, Bonome, Tomas, Calin, George Adrian, Greshock, Joel, Yang, Nuo, Liu, Chang-Gong, Giannakakis, Antonis, Alexiou, Pangiotis, Hasegawa, Kosei, Johnstone, Cameron N., Megraw, Molly S., Adams, Sarah, Lassus, Heini, Huang, Jia, Kaur, Sippy, Liang, Shun, Sethupathy, Praveen, Leminen, Arto, Simossis, Victor A., Sandaltzopoulos, Raphael, Naomoto, Yoshio, Katsaros, Dionyssios, Gimotty, Phyllis A., DeMichele, Angela, Huang, Qihong, Bützow, Ralf, Rustgi, Anil K., Weber, Barbara L., Birrer, Michael J., Hatzigeorgiou, Artemis G., Croce, Carlo M., and Coukos, George

Published
2008
Full Text
View/download PDF

14. Association between miR-200c and the survival of patients with stage I epithelial ovarian cancer: a retrospective study of two independent tumour tissue collections

Author

Marchini, Sergio, Cavalieri, Duccio, Fruscio, Robert, Calura, Enrica, Garavaglia, Daniela, Nerini, Ilaria Fuso, Mangioni, Costantino, Cattoretti, Giorgio, Clivio, Luca, Beltrame, Luca, Katsaros, Dionyssios, Scarampi, Luca, Menato, Guido, Perego, Patrizia, Chiorino, Giovanna, Buda, Alessandro, Romualdi, Chiara, and D'Incalci, Maurizio

Published
2011
Full Text
View/download PDF

16. MicroRNAs Exhibit High Frequency Genomic Alterations in Human Cancer

Author

Zhang, Lin, Huang, Jia, Yang, Nuo, Greshock, Joel, Megraw, Molly S., Giannakakis, Antonis, Liang, Shun, Naylor, Tara L., Barchetti, Andrea, Ward, Michelle R., Yao, George, Medina, Angelica, O'Brien-Jenkins, Ann, Katsaros, Dionyssios, Hatzigeorgiou, Artemis, Gimotty, Phyllis A., Weber, Barbara L., and Coukos, George

Published
2006
Full Text
View/download PDF

21. Utility and Mechanism of SHetA2 and Paclitaxel for Treatment of Endometrial Cancer.

Author

Chandra, Vishal, Rai, Rajani, Benbrook, Doris Mangiaracina, and Katsaròs, Dionyssios

Subjects
COMBINATION drug therapy, ENDOPLASMIC reticulum, ANTINEOPLASTIC agents, HEAT shock proteins, APOPTOSIS, MITOCHONDRIA, GENE expression, CELL motility, CELL cycle, ENDOMETRIAL tumors, PACLITAXEL, CELL lines, DRUG toxicity, PHOSPHORYLATION, GLYCOLYSIS, PHARMACODYNAMICS
Abstract

Simple Summary: Incidence and death rates for endometrial cancer are steadily rising world-wide. Endometrial cancer patients at high risk for recurrence are treated with chemotherapy, which causes significant toxicity. Molecularly targeted drugs have been found to cause less toxicity than chemotherapy. We studied a low-toxicity drug, called SHetA2, which targets three heat shock A proteins that are highly mutated in endometrial cancers. Our results demonstrated that SHetA2 inhibits endometrial cancer cells and tumors, and enhances therapeutic effects of paclitaxel without increasing toxicity. This information supports development of clinical trials to test if combining SHetA2 with paclitaxel can increase the paclitaxel therapeutic effect without increasing toxicity, or allows a lowered paclitaxel dose to achieve the same level of therapeutic effect, but with reduced toxicity. Our new knowledge about how SHetA2 works can be translated into development of biomarkers to predict with patients would most likely benefit from SHetA2-based therapy. Endometrial cancer patients with advanced disease or high recurrence risk are treated with chemotherapy. Our objective was to evaluate the utility and mechanism of a novel drug, SHetA2, alone and in combination with paclitaxel, in endometrial cancer. SHetA2 targets the HSPA chaperone proteins, Grp78, hsc70, and mortalin, which have high mutation rates in endometrial cancer. SHetA2 effects on cancerous phenotypes, mitochondria, metabolism, protein expression, mortalin/client protein complexes, and cell death were evaluated in AN3CA, Hec13b, and Ishikawa endometrial cancer cell lines, and on growth of Ishikawa xenografts. In all three cell lines, SHetA2 inhibited anchorage-independent growth, migration, invasion, and ATP production, and induced G1 cell cycle arrest, mitochondrial damage, and caspase- and apoptosis inducing factor (AIF)-mediated apoptosis. These effects were associated with altered levels of proteins involved in cell cycle regulation, mitochondrial function, protein synthesis, endoplasmic reticulum stress, and metabolism; disruption of mortalin complexes with mitochondrial and metabolism proteins; and inhibition of oxidative phosphorylation and glycolysis. SHetA2 and paclitaxel exhibited synergistic combination indices in all cell lines and exerted greater xenograft tumor growth inhibition than either drug alone. SHetA2 is active against endometrial cancer cell lines in culture and in vivo and acts synergistically with paclitaxel. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

22. Salvage Radiation for Pelvic Relapse after Surgically Treated Endometrial Cancer.

Author

Lindemann, Kristina, Smogeli, Elisabeth, Småstuen, Milada Cvancarova, Bruheim, Kjersti, Trovik, Jone, Nordberg, Terje, Kristensen, Gunnar B., Werner, Henrica M. J., Nakken, Esten, and Katsaròs, Dionyssios

Subjects
RESEARCH, CONFIDENCE intervals, CANCER relapse, MEDICAL cooperation, RETROSPECTIVE studies, TREATMENT effectiveness, ENDOMETRIAL tumors, KAPLAN-Meier estimator, DESCRIPTIVE statistics, SALVAGE therapy, PROPORTIONAL hazards models
Abstract

Simple Summary: This multicenter retrospective study aimed to describe the outcomes of patients with endometrial cancer after central pelvic/vaginal relapse treated with radical radiotherapy (RT). We included 139 patients with a median follow-up time of 6.66 years. Patients were treated with external beam radiotherapy to elective pelvic lymph-node regions and boost to the pelvic tumor. During follow-up, 55 (39.6%) patients developed a second relapse, the majority (75%) with disease sites outside the radiation field. Risk group at primary diagnosis and type of boost administration were independent predictors of progression-free and overall survival. Five-year overall survival for the whole cohort was 68% (95% CI: 59–75%). The majority of isolated pelvic recurrences in RT-naive women with EC can be successfully salvaged by RT but survival in high-risk patients remains suboptimal. Individualizing of adjuvant treatment in first line and better treatment alternatives at relapse are important to ultimately improve survival. (1) Background: This study evaluated the clinical outcome after salvage radiotherapy for first pelvic relapse after endometrial cancer (EC). (2) Methods: This multicenter retrospective study included EC patients with first central pelvic relapse without lymph node involvement treated with curative intent. Progression-free (PFS) and overall survival (OS) were calculated with the Kaplan–Meier method and possible predictive factors for risk of relapse and mortality were identified using the Cox model. (3) Results: We included 139 patients with median EQD2 (Equivalent Dose in 2 Gy fractions) to the clinical target volume of 70.0 Gy. During follow up of median 6.66 years, 39.6% patients developed a second relapse. Risk group classification at primary diagnosis based on histology, grading and FIGO stage and how the pelvic tumor boost was administered were independently associated with PFS and OS. Five-year OS was 68% (95% CI (59–75)) for the whole cohort. Five-year OS was 88% (95% CI (75–94)), 72% (95% CI (55–84)) and 38% (95% CI (15–60)) for the stage I low-, intermediate- and high-risk group, respectively. (4) Conclusions: The majority of central pelvic recurrences in RT-naive EC women can be successfully salvaged with radiotherapy. However, survival in patients with high-risk disease remains poor and warrants a more individualized approach to optimize outcome. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results